Gastroenterology

Only 12% of SER-109 treated patients had a recurrence, compared to 40% of the placebo group.

The endomina system can be affixed to various testing standard endoscopies for a bendable therapeutic channel.

There are several barriers that prevent better HCV care, including availability and access to diagnostic and monitoring tests and the requirement for frequent medical visits during treatment.

Periprocedural antimicrobial prophylaxis are administered and in some cases continued for extended periods of time while the patient has a surgical drain in place.

The 6 recommendations across 2 expert-led guidelines address the role of colonoscopy, CT scans and elective surgery, among other subjects of care.

About 25% of C difficile infections are due to community spread.

Exposure to long-term prescription opioid therapy was linked to a 3.2-fold higher risk of HCV seroconversion compared to individuals who were prescription opioid-naïve or acute.

More research is needed on how the various FODMAP diets impact the gut microbiota and IBD management.

There remains a paucity of data for very early onset pediatric IBD in the majority of countries.

The prototype is being tested in clinical trials involving live microbiota therapeutics as a treatment for recurrent C difficile infections.

Moderate to severe disease activity and extensive disease were considered independent risk factors for malnutrition in patients with IBD.

Patients who receive a solid organ transplant and develop CDI are at an increased risk for an acute kidney injury.

These changes to the previous 2013 ACG Guidelines feature evidence-based guidance for the evaluation of gastroesophageal reflux disease that include pharmacologic, lifestyle, surgical, and endoscopic management efforts.

JAK inhibitors have been effective in treating the other form of inflammatory bowel disease, ulcerative colitis.

New research published in The Journal of Emergency Medicine shows that methylnaltrexone is a great solution to opioid-induced constipation.

GI symptoms manifest in children with COVID-19 more than they do in adult patients.

TARGET-NASH as now expanded into European centers.

Treatment failure occurred in 10% of the intensive treatment group compared to 28% in the standard treatment group

Eli Lilly and Company is expected to apply for a Biologics License Application in the first half of 2022.

At least 3 companies have presented later phase data on live microbiota therapies for treating recurrent C difficile infections in 2021.

The US recommended HBV vaccines to be part of the infant immunization plan in 1991.

The rigidity of hospital settings and a lack of awareness prevents better hepatitis C virus diagnoses in the homeless population.

Bincy Abraham, MD, led the State of Science program on C difficile infections.

The treatment also has potential in Crohn's disease and rheumatoid arthritis.

The State of the Science events allows experts to come together to update on recent research for CDI.